ESAsvirastot
ESAsvirastot is a medication used to treat chronic hepatitis C virus (HCV) infection. It is a direct-acting antiviral (DAA) drug that works by inhibiting the HCV NS5A protein, which is essential for the replication of the virus. ESAsvirastot is typically used in combination with other DAAs to achieve a higher cure rate and to reduce the risk of resistance.
The drug is available in tablet form and is usually taken orally. The dosage and duration of
ESAsvirastot was approved for medical use in 2015 and has since been incorporated into various treatment regimens
The use of ESAsvirastot and other DAAs has significantly improved the outcomes for patients with chronic HCV,